QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.

LATITUDE Trial Leads to New Approval for Abiraterone

Abiraterone (brand name Zytiga) is an oral drug that interrupts androgen production in the testes, the adrenal glands, and in prostate tumors. Abiraterone is taken in combination with the steroid prednisone. The LATITUDE trial assessed the use of abiraterone for…

Read More

Evaluating Patient Risk Groups for Active Surveillance

Ongoing research continues to assess the criteria used to select patients for active surveillance. Clinical guidelines currently recommend active surveillance for men diagnosed with very low-risk and low-risk prostate cancer. Guidelines also state that men with low-volume intermediate risk disease…

Read More

Subscribe to Quest